CELLCEUTIX CORP COM STK USD0.0001 (CTIX)

1.30
0.05 3.63
OTC
Prev Close 1.35
Open 1.34
Day Low/High 1.30 / 1.35
52 Wk Low/High 0.94 / 2.05
Volume 232.14K
Exchange OTC
Shares Outstanding 122.54B
Market Cap 167.88M
Div & Yield N.A. (N.A)

Sophiris Bio Tops Dollar-Stock Gainers on Trial Success of Cancer Treatment

Shares of the urology company surge in postmarket trading Thursday.

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Cellceutix Corporation To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of...

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Cellceutix Corporation - CTIX

Rosen Law Firm, a global investor rights law firm, announces that it has filed a class action lawsuit on behalf of purchasers of Cellceutix Corporation (OTC: CTIX) securities from May 10, 2013 through August 6, 2015, all...

EQUITY ALERT: The Rosen Law Firm Announces Investigation Of Securities Claims Against Cellceutix Corporation - CTIX

The Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Cellceutix Corporation (OTC: CTIX) resulting from allegations that Cellceutix may...

Seeking Alpha Author Used Multiple Aliases to Tout Biotech Stocks

The five articles written under three different aliases all promoted Galena Biopharma.

Cellceutix Reports Production Of Its Anti-Cancer Drug Kevetrin™ Has Begun

CEO Comments on Clinical Process and Believes "The Best Is Yet to Come"

Cellceutix Reports Confidential Disclosure Agreement Signed With Major Pharmaceutical Company

Company Developing New Chemotherapy Drug Kevetrinâ¿¢ to Treat Cancers Not Responding to Existing Drugs

The Daily Interview: Online Travel Skies Getting Crowded

Legg Mason's Thomas Underwood on whether Travelocity and Expedia should worry about the airlines' new site, Orbitz.